Semaglutide Weight Management and Cardiovascular Risk Reduction
In the trial, more patients on insulin icodec reached HbA1c target
without hypoglycaemia and a longer TIR vs insulin glargine U100
Achievement of HbA₁c target after 78 weeks without hypoglycaemia¹
54.5%*
1c
Statistically significantly longer TIR for insulin icodec vs insulin
glargine U100 measured with CGM from week 74 to 78
% of patients
46.4%
7.6%
21.1%
70.2%*
10.3%
24.1%
64.8%
Once-weekly insulin icodec
Once-daily insulin glargine U100
-0.3%
-0.8%
Once-weekly insulin icodec
0.2%
0.6%
EOR=1.4 [1.06 to 1.80] 95% CI
< 54mg/dL
54-<70mg/dL
70-180mg/dL
>180-250mg/dL
Once-daily insulin glargine U100
>250 mg/dL
Achievement of HbA₁ target <7.0% without hypoglycaemia¹
Time in range
•
•
Statistically significantly more participants achieved the HbA1c
target without severe or clinically significant hypoglycaemia with
insulin icodec compared to insulin glargine U100
70-180 mg/dL from week 74 to week 78 was 70.2% with once-
weekly insulin icodec and 64.8% with once-weekly insulin glargine,
statistically significant difference in favor of once-weekly insulin
icodec vs once-daily insulin glargine U100
1 Specifically an HbA1c <7% without level 2 or 3 hypoglycaemic episodes during the prior 12 weeks; * Statistically significant difference in favour of insulin icodec.
Note: The binary response after 78 weeks is analysed using a binary logistic regression model (logit link) with treatment and region as fixed factors, and the baseline HbA1c value as covariate. For TIR: Time spent is defined as 100 times the number of recorded
measurements in a given range, divided by the total number of recorded measurements
TIR: Time in range; CGM, continuous glucose monitor; CI: Confidence interval; EOR: Estimated odds ratioView entire presentation